| HOME >> MEDICINE >> TECHNOLOGY |
All forward-looking statements reflect the Company's estimates only as of the date of this release (unless another date is indicated) and should not be relied upon as reflecting the Company's views, expectations or beliefs at any date subsequent to the date of this release. While Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if the Company's estimates change.IDENIX PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(IN THOUSANDS, EXCEPT PER SHARE DATA)(UNAUDITED)Three Months Ended
September 30,Nine Months Ended
September 30,2011201020112010Revenues:Collaboration revenue – related party
$ 1,982$
3,424$ 5,715$ 6,366Other revenue6563641,9671,421Total revenues
2,6383,7887,6827,787Operating expenses (1):Cost of revenues
5955661,7311,800Research and development
10,19011,63728,53035,548General and administrative
3,9004,44012,29314,308Restructuring charges
---------------2,238Total operating expenses14,68516,64342,55453,894Loss from operations
(12,047)(12,855)(34,872)(46,107)Other income (expense), net338(76)1,019712Loss before income taxes(11,709)(12,931)(33,853)(45,395)Income tax benefit (expense)-----1(1)(3)Net loss$(11,709)$(12,930)$(33,854)$(45,398)Basic and diluted net loss per share:($0.12)($0.18)
| SOURCE Idenix Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved |